Hospital
Onslow Memorial Hospital INC
Onslow Memorial Hospital INC was paid $23.60M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoONSLOW MEMORIAL HOSPITAL INC
JACKSONVILLE, NC 28546
JACKSONVILLE, NC 28546
33aNPI1679535496assigned 04/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.60M
24GClaims490,200
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#23 of 92
Median peer was paid$11.47M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,252 | $2.47M | |
| 2019 | 75,481 | $2.18M | |
| 2020 | 60,859 | $1.50M | |
| 2021 | 72,799 | $2.92M | |
| 2022 | 73,485 | $4.06M | |
| 2023 | 68,776 | $5.03M | |
| 2024incomplete | 61,548 | $5.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 28,787 | 27,010 | $6.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 16,080 | 14,836 | $5.80M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 33,756 | 32,026 | $4.47M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.2% | 6,174 | 5,874 | $985K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.0% | 1,174 | 1,118 | $718K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 6,975 | 6,026 | $461K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.6% | 8,203 | 2,121 | $374K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 13,849 | 12,283 | $336K |
| 80053 | Comprehensive metabolic panel | 1.4% | 38,041 | 35,314 | $326K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 43,925 | 40,640 | $324K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 1.2% | 1,780 | 1,526 | $280K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,582 | 5,163 | $197K |
109 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,990 | $193K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,530 | $190K |
| 59025 | Fetal non-stress test | <1% | 3,881 | $189K |
| J3490 | Unclassified drugs | <1% | 95,744 | $156K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 42,604 | $148K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 620 | $148K |
| 81001 | <1% | 35,633 | $119K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 51,253 | $108K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,636 | $102K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,115 | $95K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 323 | $90K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,158 | $83K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,655 | $72K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,039 | $70K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,367 | $65K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,333 | $53K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 606 | $50K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,184 | $37K |
| 94760 | <1% | 2,126 | $27K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 689 | $26K |
| 76801 | <1% | 387 | $24K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,862 | $24K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,038 | $22K |
| 84484 | <1% | 2,822 | $21K | |
| 83690 | <1% | 2,802 | $20K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 84 | $20K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 991 | $19K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,041 | $19K |
| 88307 | <1% | 334 | $17K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 81 | $17K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 819 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,240 | $15K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 76 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 501 | $12K |
| 88304 | <1% | 605 | $12K | |
| 30802 | <1% | 16 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,253 | $11K |
| 88342 | <1% | 385 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,187 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 727 | $9K |
| 99201 | <1% | 585 | $9K | |
| 87070 | <1% | 787 | $8K | |
| 93325 | <1% | 83 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 584 | $6K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 381 | $6K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 100 | $6K |
| 84703 | <1% | 549 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 142 | $5K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 52 | $5K |
| 81025 | <1% | 441 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 105 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 105 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 124 | $3K |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 32 | $3K |
| 93321 | <1% | 43 | $2K | |
| 86003 | <1% | 12 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 130 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 213 | $2K |
| 82247 | <1% | 358 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 103 | $2K |
| 99406 | <1% | 407 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 277 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 81 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 42 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 211 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 58 | $1K |
| 93971 | <1% | 137 | $1K | |
| 73630 | <1% | 24 | $1K | |
| 77073 | <1% | 13 | $1K | |
| 00142 | <1% | 30 | $986.27 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 40 | $832.37 |
| 82550 | <1% | 190 | $702.47 | |
| 81005 | <1% | 315 | $656.18 | |
| 73130 | <1% | 13 | $583.30 | |
| 80061 | Lipid panel | <1% | 37 | $524.10 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24 | $487.44 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $442.68 |
| 84112 | <1% | 14 | $435.79 | |
| V2632 | Posterior chamber intraocular lens | <1% | 56 | $429.33 |
| 80076 | <1% | 34 | $329.96 | |
| 82785 | <1% | 12 | $321.63 | |
| 83735 | <1% | 39 | $300.69 | |
| 83655 | <1% | 17 | $268.82 | |
| 82553 | <1% | 39 | $262.75 | |
| 82248 | <1% | 358 | $235.71 | |
| 86140 | <1% | 32 | $223.57 | |
| 87420 | <1% | 16 | $214.20 | |
| 80047 | <1% | 19 | $189.73 | |
| 87210 | <1% | 43 | $145.31 | |
| 83605 | <1% | 15 | $140.46 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $133.88 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 87 | $133.71 |
| 87077 | <1% | 14 | $106.50 | |
| 85027 | <1% | 16 | $102.55 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13 | $99.77 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 13 | $78.84 |
| 85730 | <1% | 17 | $66.36 | |
| 85014 | <1% | 19 | $56.65 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 94 | $54.19 |
| 87075 | <1% | 14 | $51.30 | |
| 85610 | <1% | 20 | $42.08 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13 | $32.66 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 159 | $25.52 |
| 87205 | <1% | 14 | $24.34 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 14 | $2.04 |
| 99292 | 0% | 13 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 30 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIBER, CARL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Onslow Ambulatory Services, INC. | Jacksonville, NC | $733K |
| Onslow Ambulatory Services, INC. | Jacksonville, NC | $679K |
| Onslow Ambulatory Services, INC | Jacksonville, NC | $300K |
| Onslow Ambulatory Services, INC. | Jacksonville, NC | $158K |
| Onslow Radiation Oncology LLC | Jacksonville, NC | $5K |
| Onslow Ambulatory Services, INC. | Jacksonville, NC | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.